1
|
Khananshvili D. Neuronal and astrocyte NCX isoform/splice variants: How do they participate in Na + and Ca 2+ signalling? Cell Calcium 2023; 116:102818. [PMID: 37918135 DOI: 10.1016/j.ceca.2023.102818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 10/20/2023] [Accepted: 10/22/2023] [Indexed: 11/04/2023]
Abstract
NCX1, NCX2, and NCX3 gene isoforms and their splice variants are characteristically expressed in different regions of the brain. The tissue-specific splice variants of NCX1-3 isoforms show specific expression profiles in neurons and astrocytes, whereas the relevant NCX isoform/splice variants exhibit diverse allosteric modes of Na+- and Ca2+-dependent regulation. In general, overexpression of NCX1-3 genes leads to neuroprotective effects, whereas their ablation gains the opposite results. At this end, the partial contributions of NCX isoform/splice variants to neuroprotective effects remain unresolved. The glutamate-dependent Na+ entry generates Na+ transients (in response to neuronal cell activities), whereas the Na+-driven Ca2+ entry (through the reverse NCX mode) raises Ca2+ transients. This special mode of signal coupling translates Na+ transients into the Ca2+ signals while being a part of synaptic neurotransmission. This mechanism is of general interest since disease-related conditions (ischemia, metabolic stress, and stroke among many others) trigger Na+ and Ca2+ overload with deadly outcomes of downstream apoptosis and excitotoxicity. The recently discovered mechanisms of NCX allosteric regulation indicate that some NCX variants might play a critical role in the dynamic coupling of Na+-driven Ca2+ entry. In contrast, the others are less important or even could be dangerous under altered conditions (e.g., metabolic stress). This working hypothesis can be tested by applying advanced experimental approaches and highly focused computational simulations. This may allow the development of structure-based blockers/activators that can selectively modulate predefined NCX variants to lessen the life-threatening outcomes of excitotoxicity, ischemia, apoptosis, metabolic deprivation, brain injury, and stroke.
Collapse
Affiliation(s)
- Daniel Khananshvili
- Department of Physiology and Pharmacology, Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel.
| |
Collapse
|
2
|
The downregulation of NCXs is positively correlated with the prognosis of stage II-IV colon cancer. World J Surg Oncol 2021; 19:177. [PMID: 34127021 PMCID: PMC8204472 DOI: 10.1186/s12957-021-02284-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 06/02/2021] [Indexed: 02/07/2023] Open
Abstract
Purpose Colon cancer (CC) is a very common gastrointestinal tumor that is prone to invasion and metastasis in the late stage. This study aims to observe the expression of Na+/Ca2+ exchangers (NCXs) and analyze the correlation between NCXs and the prognosis of CC. Methods Specimens of 111 stage II–IV CC patients were collected. We used western blotting, qPCR, and immunohistochemical staining to observe the distributions and expression levels of NCX isoforms (NCX1, NCX2, and NCX3) in CC and distal normal tissues. Cox proportional hazards models were used to assess prognostic factors for patients. Results The expression of NCXs in most tumor specimens was lower than that in normal tissues. The NCX expression levels in tumor tissues from the primary tumor, local lymph node metastasis sites, and distant liver metastasis sites were increasingly significantly lower than those in normal tissues. The results of the Kaplan-Meier survival curves showed that the downregulation of any NCX isoform was closely related to the worse prognosis of advanced CC. Conclusion NCXs can be used as independent prognostic factors for CC. Our research results are expected to provide new targets for the treatment of CC.
Collapse
|
3
|
Vicario M, Zanni G, Vallese F, Santorelli F, Grinzato A, Cieri D, Berto P, Frizzarin M, Lopreiato R, Zonta F, Ferro S, Sandre M, Marin O, Ruzzene M, Bertini E, Zanotti G, Brini M, Calì T, Carafoli E. A V1143F mutation in the neuronal-enriched isoform 2 of the PMCA pump is linked with ataxia. Neurobiol Dis 2018; 115:157-166. [PMID: 29655659 DOI: 10.1016/j.nbd.2018.04.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Revised: 03/21/2018] [Accepted: 04/09/2018] [Indexed: 12/13/2022] Open
Abstract
The fine regulation of intracellular calcium is fundamental for all eukaryotic cells. In neurons, Ca2+ oscillations govern the synaptic development, the release of neurotransmitters and the expression of several genes. Alterations of Ca2+ homeostasis were found to play a pivotal role in neurodegenerative progression. The maintenance of proper Ca2+ signaling in neurons demands the continuous activity of Ca2+ pumps and exchangers to guarantee physiological cytosolic concentration of the cation. The plasma membrane Ca2+ATPases (PMCA pumps) play a key role in the regulation of Ca2+ handling in selected sub-plasma membrane microdomains. Among the four basic PMCA pump isoforms existing in mammals, isoforms 2 and 3 are particularly enriched in the nervous system. In humans, genetic mutations in the PMCA2 gene in association with cadherin 23 mutations have been linked to hearing loss phenotypes, while those occurring in the PMCA3 gene were associated with X-linked congenital cerebellar ataxias. Here we describe a novel missense mutation (V1143F) in the calmodulin binding domain (CaM-BD) of the PMCA2 protein. The mutant pump was present in a patient showing congenital cerebellar ataxia but no overt signs of deafness, in line with the absence of mutations in the cadherin 23 gene. Biochemical and molecular dynamics studies on the mutated PMCA2 have revealed that the V1143F substitution alters the binding of calmodulin to the CaM-BD leading to impaired Ca2+ ejection.
Collapse
Affiliation(s)
- Mattia Vicario
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Ginevra Zanni
- Department of Neurosciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Francesca Vallese
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | | | - Alessandro Grinzato
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Domenico Cieri
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Paola Berto
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Martina Frizzarin
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Raffaele Lopreiato
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Francesco Zonta
- Shanghai Institute of Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China; Department of Biomedical Sciences, Institute of Cell Biology and Neurobiology, Italian National Research Council, 00015 Monterotondo, Rome, Italy
| | - Stefania Ferro
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Michele Sandre
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Oriano Marin
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Maria Ruzzene
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Enrico Bertini
- Department of Neurosciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - Giuseppe Zanotti
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy
| | - Marisa Brini
- Department of Biology, University of Padova, Italy.
| | - Tito Calì
- Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy; Padua Neuroscience Center (PNC), University of Padua, 35122 Padova, Italy.
| | | |
Collapse
|
4
|
Stafford N, Wilson C, Oceandy D, Neyses L, Cartwright EJ. The Plasma Membrane Calcium ATPases and Their Role as Major New Players in Human Disease. Physiol Rev 2017; 97:1089-1125. [PMID: 28566538 DOI: 10.1152/physrev.00028.2016] [Citation(s) in RCA: 92] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 01/20/2017] [Accepted: 01/23/2017] [Indexed: 02/07/2023] Open
Abstract
The Ca2+ extrusion function of the four mammalian isoforms of the plasma membrane calcium ATPases (PMCAs) is well established. There is also ever-increasing detail known of their roles in global and local Ca2+ homeostasis and intracellular Ca2+ signaling in a wide variety of cell types and tissues. It is becoming clear that the spatiotemporal patterns of expression of the PMCAs and the fact that their abundances and relative expression levels vary from cell type to cell type both reflect and impact on their specific functions in these cells. Over recent years it has become increasingly apparent that these genes have potentially significant roles in human health and disease, with PMCAs1-4 being associated with cardiovascular diseases, deafness, autism, ataxia, adenoma, and malarial resistance. This review will bring together evidence of the variety of tissue-specific functions of PMCAs and will highlight the roles these genes play in regulating normal physiological functions and the considerable impact the genes have on human disease.
Collapse
Affiliation(s)
- Nicholas Stafford
- Division of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom
| | - Claire Wilson
- Division of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom
| | - Delvac Oceandy
- Division of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom
| | - Ludwig Neyses
- Division of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom
| | - Elizabeth J Cartwright
- Division of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom
| |
Collapse
|
6
|
Rassner MP, Moser A, Follo M, Joseph K, van Velthoven-Wurster V, Feuerstein TJ. Neocortical GABA release at high intracellular sodium and low extracellular calcium: an anti-seizure mechanism. J Neurochem 2016; 137:177-89. [DOI: 10.1111/jnc.13555] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2015] [Revised: 01/14/2016] [Accepted: 01/22/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Michael P. Rassner
- Section of Clinical Neuropharmacology of the Department of Neurosurgery; University of Freiburg; Freiburg Germany
| | - Andreas Moser
- Neurochemical Research Group; Department of Neurology; University of Lübeck; Lübeck Germany
- Freiburg Institute for Advanced Studies (FRIAS); University of Freiburg; Freiburg Germany
| | - Marie Follo
- Department of Medicine I; Medical Center - University of Freiburg; Freiburg Germany
| | - Kevin Joseph
- Section of Clinical Neuropharmacology of the Department of Neurosurgery; University of Freiburg; Freiburg Germany
- Section of Neuroelectronic Systems of the Department of Neurosurgery; University of Freiburg; Freiburg Germany
| | | | - Thomas J. Feuerstein
- Section of Clinical Neuropharmacology of the Department of Neurosurgery; University of Freiburg; Freiburg Germany
- Freiburg Institute for Advanced Studies (FRIAS); University of Freiburg; Freiburg Germany
| |
Collapse
|
7
|
de Juan-Sanz J, Núñez E, Zafra F, Berrocal M, Corbacho I, Ibáñez I, Arribas-González E, Marcos D, López-Corcuera B, Mata AM, Aragón C. Presynaptic control of glycine transporter 2 (GlyT2) by physical and functional association with plasma membrane Ca2+-ATPase (PMCA) and Na+-Ca2+ exchanger (NCX). J Biol Chem 2014; 289:34308-24. [PMID: 25315779 DOI: 10.1074/jbc.m114.586966] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Fast inhibitory glycinergic transmission occurs in spinal cord, brainstem, and retina to modulate the processing of motor and sensory information. After synaptic vesicle fusion, glycine is recovered back to the presynaptic terminal by the neuronal glycine transporter 2 (GlyT2) to maintain quantal glycine content in synaptic vesicles. The loss of presynaptic GlyT2 drastically impairs the refilling of glycinergic synaptic vesicles and severely disrupts neurotransmission. Indeed, mutations in the gene encoding GlyT2 are the main presynaptic cause of hyperekplexia in humans. Here, we show a novel endogenous regulatory mechanism that can modulate GlyT2 activity based on a compartmentalized interaction between GlyT2, neuronal plasma membrane Ca(2+)-ATPase (PMCA) isoforms 2 and 3, and Na(+)/Ca(2+)-exchanger 1 (NCX1). This GlyT2·PMCA2,3·NCX1 complex is found in lipid raft subdomains where GlyT2 has been previously found to be fully active. We show that endogenous PMCA and NCX activities are necessary for GlyT2 activity and that this modulation depends on lipid raft integrity. Besides, we propose a model in which GlyT2·PMCA2-3·NCX complex would help Na(+)/K(+)-ATPase in controlling local Na(+) increases derived from GlyT2 activity after neurotransmitter release.
Collapse
Affiliation(s)
- Jaime de Juan-Sanz
- From the Department of Biochemistry, Weill Cornell Medical College, New York, New York 10065
| | - Enrique Núñez
- the Centro de Biología Molecular "Severo Ochoa," Universidad Autónoma de Madrid, Consejo Superior de Investigaciones Científicas, 28049-Madrid, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, 46009-Valencia, Spain, the IdiPAZ-Hospital, Universitario La Paz, 28046-Madrid, Spain, and
| | - Francisco Zafra
- the Centro de Biología Molecular "Severo Ochoa," Universidad Autónoma de Madrid, Consejo Superior de Investigaciones Científicas, 28049-Madrid, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, 46009-Valencia, Spain, the IdiPAZ-Hospital, Universitario La Paz, 28046-Madrid, Spain, and
| | - María Berrocal
- the Departamento de Bioquímica y Biología Molecular y Genética, Facultad de Ciencias, Universidad de Extremadura, 06006-Badajoz, Spain
| | - Isaac Corbacho
- the Departamento de Bioquímica y Biología Molecular y Genética, Facultad de Ciencias, Universidad de Extremadura, 06006-Badajoz, Spain
| | - Ignacio Ibáñez
- the Centro de Biología Molecular "Severo Ochoa," Universidad Autónoma de Madrid, Consejo Superior de Investigaciones Científicas, 28049-Madrid, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, 46009-Valencia, Spain, the IdiPAZ-Hospital, Universitario La Paz, 28046-Madrid, Spain, and
| | - Esther Arribas-González
- the Centro de Biología Molecular "Severo Ochoa," Universidad Autónoma de Madrid, Consejo Superior de Investigaciones Científicas, 28049-Madrid, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, 46009-Valencia, Spain, the IdiPAZ-Hospital, Universitario La Paz, 28046-Madrid, Spain, and
| | - Daniel Marcos
- the Departamento de Bioquímica y Biología Molecular y Genética, Facultad de Ciencias, Universidad de Extremadura, 06006-Badajoz, Spain
| | - Beatriz López-Corcuera
- the Centro de Biología Molecular "Severo Ochoa," Universidad Autónoma de Madrid, Consejo Superior de Investigaciones Científicas, 28049-Madrid, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, 46009-Valencia, Spain, the IdiPAZ-Hospital, Universitario La Paz, 28046-Madrid, Spain, and
| | - Ana M Mata
- the Departamento de Bioquímica y Biología Molecular y Genética, Facultad de Ciencias, Universidad de Extremadura, 06006-Badajoz, Spain
| | - Carmen Aragón
- the Centro de Biología Molecular "Severo Ochoa," Universidad Autónoma de Madrid, Consejo Superior de Investigaciones Científicas, 28049-Madrid, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, 46009-Valencia, Spain, the IdiPAZ-Hospital, Universitario La Paz, 28046-Madrid, Spain, and
| |
Collapse
|